* If you want to update the article please login/register
Contrary to conventional wisdom, new evidence shows that neoadjuvant systemic therapy for invasive breast cancer may reduce co-existing ductal carcinoma in-situ, which may facilitate de-escalation of breast resections. The aim of this systematic review was to determine the eradication rate of DCIS by NSTs that have been used for invasive breast cancer. Only one research looking at the effect of neoadjuvant endocrine therapy met the search criteria. There was no significant difference in the eradication rate of DCIS among triple negative breast cancer and HER2-positive disease versus HER2-positive disease.
Source link: https://doi.org/10.3390/cancers15010013
A heterogenous group of lesions with varying malignant potential is Ductal carcinoma in situ. The tendency to be less aggressive in terms of surgery has followed the pattern of events that have been observed in the treatment of invasive breast carcinomas. When all patients with DCIS are considered, the overall mortality is extremely low, only around 1u20132%. Breast-conserving surgery is only curative in 75 percent, on the other hand; 55% of the local recurrences have been invasive, with a mortality rate of 12u201315%. The Van Nuys Prognostic Index, which has been recently updated, is a tool that measures measurable prognostic variables that can be used in decision-making during medical diagnosis. Human breast tumors' cellular biology and gene expression profiling have been gaining valuable insight into the relationship between DCIS and invasive breast cancer.
Source link: https://doi.org/10.4081/oncol.2010.191
Ductal carcinoma in situ of the breast is a noninvasive form of breast cancer that has risen in prevalence in the last two decades due to screening mammography. DCIS now accounts for 20 percent of all newly diagnosed breast cancer cases, with 20 percent now representing 20 percent. Several randomized trials have reported a decrease in ipsilateral breast tumor recurrence in patients treated with local excision followed by radiation therapy, relative to local excision alone. Ongoing clinical trials are trying to identify a subgroup of DCIS patients at risk for recurrence who will not benefit from radiation therapy. Partial breast irradiation is now being investigated as a treatment option for DCIS patients, in addition, because the majority of ipsilateral breast tumor recurrences occur near the original primary tumor site. Randomized studies have shown that Tamoxifen can reduce the risk of ipsilateral and contralateral breast tumor recurrences, although recent clinical trials have focused on aromatase inhibitors.
Source link: https://doi.org/10.4081/oncol.2009.237
Abstract of Malignant Transformation The most common form of mature cystic teratoma with squamous cell carcinoma being the most common variant. In situ, we report a new case of squamous cell carcinoma. Case Study A 62-year-old woman was admitted for an abdomino-pelvic tumor, and she underwent a left salpingo-oophorectomy.
Source link: https://doi.org/10.1186/1757-2215-4-5
Due to the high prevalence of breast cancers, ductal carcinoma in situ has become a non-negligible component of breast cancers. Methods of Investigations A comprehensive review of 389 patients with DCIS or DCIS with invasive ductal carcinoma was reviewed. Based on pathology, the 324 patients in the training cohort were divided into invasion and non-invasion groups. When investigating changes in the tumor heterogeneity during invasion, the disparities between DCIS and matched IDC were explored in the invasion study. Patients in invasion and non-invasion groups were similar in baseline characteristics, and no statistically significant differences were found for DCIS immunohistochemical markers. IDC's Ki-67 of IDC was significantly higher than that of matched DCIS p 0. 001. In comparison to the in-situ ones, Invasion tumor cells have a greater proliferative capacity. Between DCIS and matched IDC, there are linear correlations in HER2 expression and histological scores. DCIS subclones with different histological qualities will develop into invasive carcinomas in separate.
Source link: https://doi.org/10.7717/peerj.13966
Both benign and malignant diseases are present in this broad group, which can differ both medically and radiologically. Ductal disease is a common disorder that can occur both locally and morphologically. Ductal carcinoma in situ is a noninvasive breast cancer disease that accounts for 20% of newly diagnosed breast cancer patients. We present a case of a 72-year-old female with serous and bloody discharge and histology revealing intermediate grade ductal carcinoma in situ involving an intraductal papilloma.
Source link: https://doi.org/10.1016/j.radcr.2022.11.014
The literature on this technique in the treatment of DCIS is scarce, oncoplastic level II breast-conserving surgery allowing for larger excisions than standard breast-conserving surgery. This review compares OPS2 to conservative mastectomy in patients undergoing surgery for significant DCIS. The retrospective analysis of 147 patients who underwent either CM or OPS2 for large DCIS between 2007 and 2021 was retrospectively reviewed. In the OPS2 group, the rate of additional surgery for cosmetic optimization was dramatically lower: only 1 patient required surgical adjustments versus 24 patients in the CM group. In the OPS2 group, the mean hospital stay was lower. The PRO report produced higher results in the OPS2 group, which had statistical significance in the sexual health-being module. In the OPS2 group, skin sensitivity loss was also markedly lower.
Source link: https://doi.org/10.3390/cancers14225624
Although carcinoma in situ has long been recognized as a well-established concept and diagnostic category, for reasons unknown sebaceous carcinoma in situ, however, no one has been recognized in general pathology or dermatopathology. Recognizing sebaceous carcinoma in situ as a legitimate concept and diagnostic entity will help avoid misinterpretation and subsequent treatment of such lesions.
For the treatment of high-risk non-muscle invasive bladder cancers, the detection of carcinoma in situ is vital. A total of 45 patients undergoing pre-surgical DCE-MRI and PDD-assisted endoscopic surgery were evaluated, as well as biopsies of the eight segments. The overall sensitivity and specificity for detecting CIS were 48. 2% and 81. 9%, respectively, in the DCE-MRI. For detecting CIS, we tried out two different combinations of PDD and DCE-MRI. When either the PDD or DCE-MRI were test-positive, the Positive Combination 1 was positive. When both PDD and DCE-MRI were test-positive, Combination 2 was positive but only when both PDD and DCE-MRI were test-positive.
Source link: https://doi.org/10.3390/diagnostics9030112
Background: This study was designed to assess and report the specific CT findings in patients with small pancreatic cancer, as well as carcinoma in situ. Patients who were positive for each finding were compared between small PC and benign MPD stenosis groups, according to the proportions of patients positive for each finding. The proportion of patients with partial pancreatic atrophy related to the outbreak of MPD stenosis, upstream PPA from the site of MPD stenosis & MPD abrupt stenosis was much higher in the small PC group than in the benign MPD stenosis group.
Source link: https://doi.org/10.3390/diagnostics10070445
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions